- Maze Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing small molecule precision medicines for patients with kidney and metabolic diseases.
- In 2025, Maze reported positive topline data from its Phase 2 HORIZON trial of MZE829 and announced the initiation of two additional Phase 2 trials for MZE782 in PKU and CKD expected in 2026, while also appointing Neil Kumar, Ph.D., to its Board of Directors.
- The company maintains a strong financial position with $360 million in cash and equivalents, providing a cash runway into 2028, which supports its ongoing clinical programs.
- Ideal buyers for Maze include healthcare providers and pharmaceutical companies seeking innovative treatments for kidney and metabolic diseases, addressing significant unmet medical needs in these areas.
Maze's workforce is organized across 12 departments, with a notable concentration in Sales, Operations, and Information Technology. The Sales department leads with 11 employees, followed closely by Operations with 10. This distribution indicates a strong emphasis on customer engagement and support functions, while Engineering and Marketing departments maintain smaller headcounts of 4 and 2, respectively, suggesting a balanced approach to product development and market outreach.
The geographic distribution of Maze's workforce spans 14 locations, with the highest concentration in San Francisco, CA, housing 5 employees. Other significant locations include Chicago, IL, and Mountain View, CA, each with 3 employees. The 'Other' category encompasses a substantial 35 employees, indicating a distributed workforce model that allows for remote engagement across various regions, contributing to a diverse operational footprint.
